

INFORMAZIONI PERSONALI

Fabio Gelsomino via del Pozzo 71, 41124

Modena

 059 4224982 gelsomino.fabio@aou.mo.itESPERIENZA
PROFESSIONALE

2018–alla data attuale

Dirigente Medico**DH Oncologico**

Attività clinico-assistenziale e di ricerca con particolare riferimento alle neoplasie del tratto gastro-enterico

2015 – 2017

MEDICO SPECIALISTA IN ONCOLOGIA MEDICA**Hesperia Hospital Modena**

Attività clinica inerente alla prevenzione oncologica e visite specialistiche oncologiche

2014 – 2018

MEDICO SPECIALISTA IN ONCOLOGIA MEDICA, LIBERO PROFESSIONISTA**DH oncologico, Azienda Ospedaliero Universitaria di Modena**

Attività clinico-assistenziale e di ricerca con particolare riferimento alle neoplasie del tratto gastro-enterico

ISTRUZIONE E FORMAZIONE

2002 – 2008

Dottore in Medicina e Chirurgia (110/110 e lode)

▪ Facoltà di Medicina e Chirurgia dell'Università degli Studi di Modena e Reggio Emilia

2009

Iscrizione Albo Nazionale dei Medici

2009 - 2014

Specializzazione in oncologia medica

▪ Università degli Studi di Modena e Reggio Emilia

COMPETENZE PERSONALI

Lingua madre Italiano

Lingue straniere

Inglese

Francese

Tedesco

COMPRENSIONE		PARLATO		PRODUZIONE SCRITTA
Ascolto	Lettura	Interazione	Produzione orale	
C2	C2	C2	C2	C2

Curriculum vitae

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato

Quadro Comune Europeo di Riferimento delle Lingue

Fabio Gelsomino

Competenze comunicative

Capacità di lavorare in gruppo, ottima capacità di 'organizzazione del carico di lavoro, ottima capacità di adeguamento in ambienti diversi e multiculturali, ottima capacità di relazionarsi con i colleghi, con i pazienti e con i famigliari degli stessi.

Competenze organizzative e gestionali

Ottima capacità di organizzazione del lavoro e di gestione di progetti, con particolare riferimento a studi clinici in ambito oncologico dedicati alle neoplasie del tratto gastro-enterico.

Competenze digitali

AUTOVALUTAZIONE				
Elaborazione delle informazioni	Comunicazione	Creazione di Contenuti	Sicurezza	Risoluzione di problemi
Buono	Buono	Buono	Buono	Buono

Competenze digitali - Scheda per l'autovalutazione

Conoscenza degli applicativi Microsoft e del pacchetto Office, in modo particolare Excel, PowerPoint e Word, conoscenza di base di Microsoft Office Access, ottima capacità di navigazione in Internet, ottima capacità di ricerca nei Database e nelle banche dati scientifiche presenti in Internet. Sistema operativo Windows, iOS.

- Patente di guida B

ULTERIORI INFORMAZIONI

2011 – ad oggi	Membro del Team multidisciplinare sulle neoplasie del tratto gastroenterico dell'Azienda Ospedaliero-Universitaria di Modena
2017 – ad oggi	Revisore di articoli scientifici per la rivista “ <i>Journal of Oncology</i> ”, International Journal of Biological Markers, Cancers
2017 – ad oggi	Estensore e dal 2019 segretario linee guida AIOM neoplasie neuroendocrine
2013 – 2015	Membro del Team multidisciplinare Punto Melanoma dell'Azienda Ospedaliero-Universitaria di Modena

PRESENTAZIONI ORALI

- Sulle ali del Sollevio: nuovi scenari terapeutici e gestionali del paziente con breakthrough cancer pain, Modena, 21 Aprile 2012
- AcheoloGIST III Summit. A scientific, interactive case study-based meeting on GIST management. Target therapy in GIST: a case of a long responder. Barcellona, 6 Maggio 2012.
- GEP-NETs Insights, tiro alla fune. Modena 29 Novembre 2013.
- La strategia terapeutica nelle neoplasie del TESTA COLLO ricorrente e/o metastatico: attualità e prospettive. La gestione della tossicità cutanea. Modena, 23 giugno 2015.
- Pazopanib (dati essenziali fase III – caso paradigmatico). Padova, 06-07 Novembre 2015, Amarene.
- Tumori neuroendocrini: Post ENETS 2016. Caso clinico – tumori neuroendocrini polmonari. Modena, 01 Aprile 2016
- Virtual Centre of Excellence: multidisciplinary perspectives and collaborative care in the management of gastric cancer. From palliative to simultaneous care in gastric cancer. Modena, 25 Maggio 2016
- Meet the Experts. Il carcinoma del pancreas. La malattia localmente avanzata. Ferrara, 22 Giugno 2016
- Tumori del tratto gastrointestinale: tra scienza e pratica. V Workshop nazionale. Adenocarcinoma del pancreas localmente avanzato: resecabile, borderline, non resecabile. Discussant. Bergamo, 10-11 Novembre 2016

- Stage on Site – Ottimizzazione del trattamento del carcinoma gastrico. Visite selezionate. Modena, 01-02 Dicembre 2016
- Ottimizzazione del percorso diagnostico-terapeutico nei tumori neuroendocrini. Chemioterapia: una inattesa riscoperta. Modena, 6-7 aprile 2017
- Ottimizzazione del percorso diagnostico-terapeutico nei tumori neuroendocrini. Cosa ci aspettiamo dalla ricerca. Modena, 6-7 aprile 2017
- Ottimizzazione del percorso diagnostico-terapeutico nei tumori neuroendocrini. Casi Clinici. Modena, 6-7 aprile 2017.
- Tumori del tratto gastrointestinale: tra scienza e pratica. VI workshop nazionale. Il tumore gastrico T4, istotipo diffuso. Modena, 18-19 aprile 2017
- Advisory Board Vectibix. Modena, 10 Aprile 2017
- Breakthroughs in gastrointestinal cancer treatment. Session I – Colorectal Cancer. Immunotherapy and new perspectives. Chieti, 19 Ottobre 2017.
- Ottimizzazione del percorso diagnostico-terapeutico nei tumori neuroendocrini. Casi Clinici. Modena, 10 aprile 2018
- Ottimizzazione del percorso diagnostico-terapeutico nei tumori neuroendocrini. Prospettive della ricerca. Modena, 11 aprile 2018
- Stage on Site – Ottimizzazione del trattamento del carcinoma gastrico. Chirurgo, oncologo e radioterapista nella malattia resecabile. I diversi punti di vista. Modena, 24 Maggio 2018
- Gruppo di Miglioramento (FSC). Clinical Audit: trattamento con EGFRi del paziente oncologico con cancro metastatico al colon retto Strategia di trattamento con EGFRi: Rechallenge. Bologna, 24 Giugno 2018.
- Tumori rari ma non troppo. I sarcomi. Modena, 16 Giugno 2018. Mirandola (MO), 29 Settembre 2018. Savignano sul Panaro (MO), 27 Ottobre 2018.
- I numeri del cancro in Emilia Romagna: ambiente, stili di vita, screening. Focus su tumori del polmone e colon-retto. IV sessione: cancro del colon-retto. Profili molecolari e trattamento. Modena, 23 Novembre 2018.
- Dealing with NEN 2019. Discussione multidisciplinare: NET polmonari. Firenze 7-8 febbraio 2019.
- Tumori del tratto gastrointestinale: tra scienza e pratica. VII Workshop Nazionale. VI Sessione: il confronto sui casi clinici. Carcinoma del colon con metastasi peritoneali. Discussant. Bergamo, 23-24 Maggio 2019.
- Stage on site, progetto GIME. Ottimizzazione del trattamento del carcinoma gastrico. Il carcinoma gastrico resecabile. La realtà quotidiana in un centro di II/III livello: ciò che si fa e ciò che si dovrebbe fare. Terapia peri-operatoria e terapia adiuvante: l'esperienza del centro nel triennio 2016-2018. Sogni e incubi dell'oncologo medico e quali vantaggi/svantaggi per i pazienti. Modena, 18-19 Giugno 2019.
- Workshop sul trattamento dei sarcomi dei tessuti molli e dei sarcomi uterini. Responsabili scientifici: dr. Gabriele Luppi e dr. Fabio Gelsomino. Modena, 20 Giugno 2019.
- 2nd International Translational Course in Rare Cancers (ITCRC). Session V. Neuroendocrine Neoplasms. Multidisciplinary Panel Discussion. Meldola, 17 Settembre 2019.
- 1° corso IEO sui tumori neuroendocrini funzionanti. Linee guida & position statement. Le sindromi correlate ai NET sono adeguatamente trattate nelle linee guida/position statement: analisi critica. Milano, 25 Settembre 2019.
- Sessione Educazionale: Tumori Neuroendocrini (NET). Aggiornamento Linee Guida AIOM. XXI Congresso Nazionale AIOM. Roma, 25-27 Ottobre 2019.

PUBBLICAZIONI

- Temozolamide as monotherapy in patients with metastatic neuroendocrine tumors: experience in seven cases. A. Fontana, F. Bertolini, L. Scarabelli, S. Zironi, R. Depenni, **F. Gelsomino**, G. Luppi, P.F. Conte World Congress on Gastrointestinal Cancer 2011, abstract p0163. Volume 22 | Supplement 5 | June 2011 doi:10.1093/annonc/mdr287. *Abstract*.
- The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. G. Ponti, G. Pellacani, A. Tomasi, **F. Gelsomino**, A. Spallanzani, R. Depenni, S. Al Jalbout, L. Simi, L.

Garagnani, S. Borsari, A. Conti, C. Ruini, A. Fontana, G. Luppi. J Clin Pathol 2013;66:5 441-445; doi: 10.1136/jclinpath-2012-201345. *Original Article*.

- A phase Ib study of everolimus, 5-Fluorouracil (5-FU) and pelvic radiotherapy (RT) as neo-adjuvant treatment for locally advanced rectal cancer (LARC). F. Bertolini, E. Pettorelli, B. Meduri, S. Zironi, A. Fontana, **F. Gelsomino**, E. Mazzeo, R. Depenni, A. Spallanzani, P.F. Conte, G. Luppi. Annals of Oncology 25 (Supplement 4): iv167–iv209, 2014 doi:10.1093/annonc/mdl333.93. *Abstract*.
- Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas. Ponti G, Pellacani G, Tomasi A, Loschi P, Luppi G, **Gelsomino F**, Longo C. Dis Markers. 2014;2014:671283.. Epub 2014 Jan 23. Erratum in: Dis Markers. 2014;2014:246751. Giovanni, Ponti [corrected to Ponti, Giovanni]; Giovanni, Pellacani [corrected to Pellacani, Giovanni]; Aldo, Tomasi [corrected to Tomasi, Aldo]; Pietro, Loschi [corrected to Loschi, Pietro]; Gabriele, Luppi [corrected to Luppi, Gabriele]; Fabio, Gelsomino [corrected to Gelsomino, Fabio]; Caterina, Longo [corrected to Longo, Caterina]. Dis Markers. 2014;2014:671283; doi: 10.1155/2014/671283. *Original Article*.
- Chemotherapy with capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NENs): an Italian multicenter retrospective analysis. Francesca Spada, Lorenzo Antonuzzo, Riccardo Marconcini, **Fabio Gelsomino**, Caterina Fumagalli, Luca Messerini, Francesco Di Costanzo, Sergio Ricci, Gabriele Luppi, Anna Maria Frezza, Salvatore Galdy, Chiara Alessandra Cella, Massimo Barberis, Nicola Fazio. ASCO Annual Meeting 2015. Abstract e15174. Doi: 10.1200/jco.2015.33.15; suppl.e15174 Journal of Clinical Oncology 33, no. 15. *Abstract*.
- Everolimus in locally advanced rectal cancer (E-LARC study, Ib): biomarkers evaluation. A. Fontana, B. Federica, L. Reggiani-Bonetti, E. Pettorelli, S. Noventa, B. Meduri, **F. Gelsomino**, S. Zironi, A. Spallanzani, E. Mazzeo, A. Maiorana, P. Conte, G. Luppi. Annals of Oncology 26 (Supplement 6): vi36–vi52, 2015. <https://doi.org/10.1093/annonc/mdv340.39>. *Abstract*.
- Long-term survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide in a named patient programs (NPP). A.V. Tamma, A. Guida, C. Masini, C. Omarini, V. Clo', **F. Gelsomino**, P. Mighali, R. Sabbatini. Annals of Oncology 26 (Supplement 6): vi53–vi66, 2015. <https://doi.org/10.1093/annonc/mdv341.36>. *Abstract*.
- The role of the activation of mTOR pathway in patients with advanced neuroendocrine tumors treated with everolimus. **F. Gelsomino**, G. Rossi, A. Spallanzani, F. Bertolini, A. Fontana, V.A. Tamma, S. Zironi, R. Depenni, K. Di Emidio, G. Luppi. Annals of Oncology 26 (Supplement 6):vi132–vi151, 2015. <https://doi.org/10.1093/annonc/mdv348.23>. *Abstract*.
- The perception of health-related quality of life in colon cancer patients during chemotherapy: differences between men and women. Domati F, Luppi G, Reggiani-Bonetti L, Zironi S, Depenni R, Fontana A, **Gelsomino F**, de Leon MP. Intern Emerg Med. 2015 Jun;10(4):423-9; doi: 10.1007/s11739-014-1174-4. *Original Article*.
- BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features? Ponti G, Tomasi A, Maiorana A, Ruini C, Maccaferri M, Cesinaro AM, Depenni R, Manni P, **Gelsomino F**, Giusti F, Garagnani L, Pellacani G. Appl Immunohistochem Mol Morphol. 2016 Jan;24(1):30-4; doi: 10.1097/PAI.0000000000000153. *Original Article*.
- Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. Spada F, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A, Ricci S, Di Costanzo F, Fontana A, **Gelsomino F**, Luppi G, Nobili E, Galdy S, Cella CA, Sonzogni A, Pisa E, Barberis M, Fazio N. Neuroendocrinology. 2016;103(6):806-14; doi: 10.1159/000444087. *Original Article*.
- Systemic therapies in metastatic pancreatic neuroendocrine neoplasms (PNENs): is there a right sequence? A case report and review of the literature. Francesca Spada, **Fabio Gelsomino**, Annalisa Fontana, Gabriele Luppi, Anna Maria Frezza, Antonio Ungaro, Nicola Fazio. Eur. J. Oncol.; Vol. 21, n. 1, pp. 75-81, 2016. *Review Article*.
- Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Passardi A, Scarpi E, Cavanna L, Dall'Agata M, Tassinari D, Leo S, Bernardini I, **Gelsomino F**, Tamperi S, Brandes AA, Tenti E, Vespignani R, Frassinetti GL, Amadori D, De Giorgi U. Oncotarget. 2016 May 31;7(22):33210-9; doi: 10.18632/oncotarget.8901. *Original Article*.
- Targeted agents in patients with metastatic renal cell carcinoma on dialysis: myths and reality. Guida A, Cosmai L, **Gelsomino F**, Masini C, Sabbatini R, Porta C. EMJ Nephrol. 2016;4[1]:66-77. *Review Article*.
- Caso clinico di un paziente lungosopravvissente trattato in I linea con FOLFIRI + cetuximab per carcinoma del colon metastatico. **F. Gelsomino**. Evidenze- casi clinici in oncologia. ISSN 2239-3102. Volume IV – n. 1/2016. *Original Article*.
- Clinical and pathological features of rare histological exocrine pancreatic cancers (PCs): a retrospective multicentric analysis. Silvestris N, Brunetti O, Marchetti P, Mazzuca F, Vasile E, **Gelsomino F**, Zanon S, Gardini Casadei A, Milella M, Basile D, Barni S, Scartozzi M, Laffi A, Delfanti S, Cella C, De Vita F, Giusi G, Lorusso V, Scarpa A, Cascinu S. XVIII National Congress of Medical Oncology 2016, abstract B13. Ann Oncol (2016) 27 (suppl 4): iv21. <https://doi.org/10.1093/annonc/mdw333.13>. *Abstract*.

- Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m). Salvatore L, Ciardiello F, Cascinu S, Sobrero A, Banzi C, Barone C, **Gelsomino F**, Maiello E, Siena S, Bergamo F, Carteni G, Di Costanzo F, Di Bartolomeo M, Rimassa L, Russo A, Moscovici M, Van Cutsem E, Grothey A, Zaniboni A. XVIII National Congress of Medical Oncology 2016, abstract D27. Ann Oncol (2016) 27 (suppl 4): iv47-iv48. <https://doi.org/10.1093/annonc/mdw335.27>. *Abstract*.
 - BRAF, NRAS and C-KIT mutations segregate distinct clinical and histopathological profiles in patients with melanoma. Greco S, Depenni R, Ponti G, Cerioli D, Iattoni E, **Gelsomino F**, Luppi G, Dominici M, Pellacani G, Cascinu S. XVIII National Congress of Medical Oncology 2016, abstract M07. Ann Oncol (2016) 27 (suppl 4): iv90-iv91. <https://doi.org/10.1093/annonc/mdw341.07>. *Abstract*.
 - The evolving role of microsatellite instability in colorectal cancer: A review. **Gelsomino F**, Barbolini M, Spallanzani A, Pugliese G, Cascinu S. Cancer Treat Rev. 2016 Dec;51:19-26; doi: 10.1016/j.ctrv.2016.10.005. *Review Article*.
 - A dose finding and biomarker evaluation phase Ib study of Everolimus in association with 5-FU and pelvic radiotherapy as neo-adjuvant treatment for locally advanced rectal cancer (E-LARC Study). **Gelsomino F**, Bertolini F, Luppi G, Spallanzani A, Pettorelli E, Reggiani Bonetti L, Meduri B, Manco G, Conte P, Cascinu S. Clinical Colorectal Cancer; doi: 10.1016/j.clcc.2017.03.011. *Original Article*.
- Gastric carcinoma: an evolutionary scenario. **Gelsomino F**, Spallanzani A, De Vita F, Di Bartolomeo M, Gavazzi C, Rimassa L, Cascinu S. Recent Prog Med. 2017 Mar;108(3):120-127; doi: 10.1701/2656.27234. *Review Article*.
- Advanced gastric cancer: is there an optimal chemotherapy regimen? Kalliopi Androkou, Massimiliano Salati, Annalisa Fontana, Andrea Spallanzani, Stefania Pipitone, **Fabio Gelsomino**, Monica Barbolini, Stefano Cascinu. Expert Review of Quality of Life in Cancer Care. 2:2, 123-132, doi: 10.1080/23809000.2017.1313683. *Review Article*.
 - The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab. M. Puzzoni, L. Demurtas, R. Giampieri, P. Ziranu, V. Pusceddu, A. Mandolesi, C. Cremolini, G. Masi, **F. Gelsomino**, C. Antoniotti, C. Loretelli, F. Meriggi, A. Zaniboni, A. Falcone, S. Cascinu, M. Scartozzi. XIX National Congress of Medical Oncology 2017, Abstract A22. Ann Oncol, Volume 28, Issue suppl_6, 1 October 2017. <https://doi.org/10.1093/annonc/mdx422.021>. *Abstract*.
 - The prognostic impact of sidedness across all stages during the last 20 years: the "Modena Cancer Registry" experience. A. Spallanzani, **F. Gelsomino**, F. Caputo, M. Salati, L. Reggiani Bonetti, F. Domati, K. Andrikou, A. Fontana, K. Di Emidio, C. Baldessari, G. Pugliese, S. Bettelli, G. Luppi, S. Cascinu. XIX National Congress of Medical Oncology 2017, Abstract A23. Ann Oncol, Volume 28, Issue suppl_6, 1 October 2017. <https://doi.org/10.1093/annonc/mdx422.022>. *Abstract*.
 - Outcome and prognostic factors after resection of liver metastases in patients with colorectal cancer. C. Baldessari, A. Spallanzani, **F. Gelsomino**, S. Bettelli, G. Pugliese, M. Salati, F. Caputo, K. Andrikou, A. Fontana, K. Di Emidio, M. Napolitano, S. Kaleci, G. Luppi, S. Cascinu. XIX National Congress of Medical Oncology 2017, Abstract A37. Ann Oncol, Volume 28, Issue suppl_6, 1 October 2017. <https://doi.org/10.1093/annonc/mdx422.036>. *Abstract*.
 - Sidedness influences prognosis in colon cancer patients receiving an adjuvant therapy. A GISCAD analysis from three randomized trials including 5234 patients. **F. Gelsomino**, V. Torri, A. Zaniboni, R. Labianca, A. Sobrero, D. Poli, L. Frontini, S. Cascinu. XIX National Congress of Medical Oncology 2017, Abstract A6. Ann Oncol, Volume 28, Issue suppl_6, 1 October 2017. <https://doi.org/10.1093/annonc/mdx422.005>. *Abstract*.
 - The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. Demurtas L, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Mandolesi A, Cremolini C, Masi G, **Gelsomino F**, Antoniotti C, Loretelli C, Meriggi F, Zaniboni A, Falcone A, Cascinu S, Scartozzi M. Br J Cancer. 2017 Jul 25;117(3):315-321. doi: 10.1038/bjc.2017.178. *Original Article*.
 - Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Passardi A, Scarpi E, **Gelsomino F**, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciari C, Tassinari D, Ragazzini A, Frassinetti GL, Valgiusti M, Ulivi P, Amadori D. Sci Rep. 2017 Sep 5;7(1):10426. doi: 10.1038/s41598-017-11048-9. *Original Article*.
 - Malignant transformation of a tailgut cyst. Manco G, Giliberti G, Rolando G, **Gelsomino F**, Zunarelli E, Rossi A. Ann Ital Chir. 2017 Jul 5;6. pii: S2239253X17027116. *Review Article*.
 - Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Campana D, Walter T, Pusceddu S, **Gelsomino F**, Graillot E, Prinzi N, Spallanzani A, Fiorentino M, Barritault M, Dall'Olio F, Brighi N, Biasco G. Endocrine. 2018 Jun;60(3):490-498. *Original Article*.
 - Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, **Gelsomino F**, Aglietta M, Morse MA, Van

Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledezne JM, Cao ZA, Kamble S, Kopetz S, André T. J Clin Oncol. 2018 Mar 10;36(8):773-779. *Original Article*.

- Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconicini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, Spada F, Gritti S, Femia D, **Gelsomino F**, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F. Pancreatology. 2018 Mar;18(2):198-203. *Original Article*.
- Histopathological variables in liver metastases of patients with stage IV colorectal cancer: potential prognostic relevance of poorly differentiated clusters. Lioni S, Bonetti LR, Bettelli S, Spallanzani A, **Gelsomino F**, Barresi V. Hum Pathol. 2018 Apr 28. pii: S0046-8177(18)30148-5. *Original Article*.
- Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal? Marta Schirripa, Paola Bionon, Francesco Cortiula, Maria Simona Pino, Federica Urbano, Carlotta Antonioti, Salvatore Corallo, **Fabio Gelsomino**, Armando Orlandi, Giada Munari, Umberto Malapelle, Massimo Rugge, Claudia Mescoli, Luca Reggiani Bonetti, Giovanni Lanza, Angelo Paolo Dei Tos, Giovanna De Maglio, Vittorina Zagonel, Fotios Loupakis, Matteo Fassan. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 3590) and Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018. *Abstract*.
- Immunotherapy in the treatment of colorectal cancer: a new kid on the block. Andrea Spallanzani, **Fabio Gelsomino**, Francesco Caputo, Chiara Santini, Kalliopi Andrikou, Giulia Orsi, Margherita Rimini, Stefania Pipitone, Laura Riggi, Camilla Bardasi, Massimiliano Salati, Stefano Cascinu. J Cancer Metastasis Treat 2018;4:28. *Review Article*.
- Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. Brighi N, La Rosa S, Rossi G, Grillo F, Pusceddu S, Rinzivillo M, Spada F, Tafuto S, Massironi S, Faggiano A, Antonuzzo L, Santini D, Sessa F, Maragliano R, **Gelsomino F**, Albertelli M, Vernieri C, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D. Ann Surg. 2018 Jul 10. doi: 10.1097/SLA.0000000000002939. [Epub ahead of print]. *Original Article*.
- P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. M Puzzoni, L Demurtas, P Ziranu, E Lai, R Giampieri, L Faloppi, A Mandolesi, C Cremolini, G Masi, **F Gelsomino**, S Mariani, A Cubeddu, L Casula, N Liscia, V Pusceddu, C Antonioti, C Loretelli, F Meriggi, A Zaniboni, A Falcone, S Cascinu, M Scartozzi. Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018. AIOM 2018. *Poster*.
- Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial. Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I, **Gelsomino F**, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassinetti GL, Amadori D, Passardi A. Onco Targets Ther. 2018 Aug 29;11:5261-5268. *Original Article*.
- Lenvatinib as a therapy for unresectable hepatocellular carcinoma. Spallanzani A, Orsi G, Andrikou K, **Gelsomino F**, Rimini M, Riggi L, Cascinu S. Expert Rev Anticancer Ther. 2018 Nov;18(11):1069-1076. *Review Article*.
- To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer. **Gelsomino F**, Spallanzani A, Orsi G, Caputo F, Santini C, Cascinu S. Crit Rev Oncol Hematol. 2018 Dec;132:154-160. *Review Article*.
- Magnetic resonance imaging performed before and after preoperative chemoradiotherapy in rectal cancer: predictive factors of recurrence and prognostic significance of MR-detected extramural venous invasion. Prampolini F, Taschini S, Pecchi A, Sani F, Spallanzani A, **Gelsomino F**, Kaleci S, Torricelli P. Abdom Radiol (NY). 2018 Nov 27. *Original Article*.
- Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient. Baldessari C, **Gelsomino F**, Spallanzani A, Pugliese G, Reggiani Bonetti L, Bettelli S, Cascinu S. Gastrointest Tumors. 2018 Sep;5(1-2):14-20. *Review Article*.
- Manuale di Oncologia Medica. Edizioni Minerva Medica. Capitolo 15: Neoplasie dello stomaco. S. Cascinu, M. Rimini, K. Andrikou, M. Salati, A. Spallanzani, **F. Gelsomino**.
- Clinico-pathological and molecular characterization of BRAF mutant patients: are all BRAF Mutations the same? Schirripa M, Bionon P, Cortiula F, Pino M.S, Urbano F, Antonioti C, Corallo S, **Gelsomino F**, Orlandi A, Munari G, Malapelle U, Rugge M, Mescoli C, Reggiani Bonetti L, Lanza G, Dei Tos A.P, De Maglio G, Zagonel V, Loupakis F and Fassan M. Tumori Journal. Volume 104, 2018 4S. Abstract Book of the 20th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract B04*.
- Clinical and molecular characterization of mismatch repair deficient metastatic colorectal cancer: results from a large multicenter Italian collaboration, the MISSION platform. Prete A.A, Di Maio M, Intini R, Schirripa M, Bergamo F, Bionon P, Marino D, Borelli B, Depetris I, Cagnazzo C, Leone F, Spallanzani A, **Gelsomino F**, Cascinu S, Corallo S, Fassan M,

Mescoli C, Zagonel V, Lonardi S and Loupakis F. Tumori Journal. Volume 104, 2018 4S. Abstract Book of the 20th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract B07.*

- The role of primary tumour location in the recurrence rate of metachronous metastasis of colon cancer. Rimini M, Bardasi C, **Gelsomino F**, Andrikou K, Reggiani Bonetti L, Caputo F, Santini C, Orsi G, Salati M, Riggi L, Pipitone S, Cascinu S and Spallanzani A. Tumori Journal. Volume 104, 2018 4S. Abstract Book of the 20th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract B17.*
- Clinical and pathological features of Colorectal Cancer in elderly patients (>75years old). Bardasi C, Santini C, **Gelsomino F**, Andrikou K, Reggiani Bonetti L, Caputo F, Rimini M, Orsi G, Salati M, Riggi L, Pipitone S, Cascinu S and Spallanzani A. Tumori Journal. Volume 104, 2018 4S. Abstract Book of the 20th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract B18.*
- Prevalence and distribution of KRAS, NRAS and BRAF mutations in patients with metastatic colorectal cancer: a "Modena Cancer Center" experience. Santini C, Caputo F, Spallanzani A, Bettelli S, Andrikou K, Salati M, Orsi G, Rimini M, Bardasi C, Riggi M.L, Pipitone S, Cascinu S and **Gelsomino F**. Tumori Journal. Volume 104, 2018 4S. Abstract Book of the 20th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract B29.*
- A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (ABTC) receiving first-line chemotherapy (1-line cht). Caputo F, Salati M, Rimini M, **Gelsomino F**, Andrikou K, Orsi G, Santini C, Bardasi C, Riggi M.L, Pipitone S, Cascinu S and Spallanzani A. Tumori Journal. Volume 104, 2018 4S. Abstract Book of the 20th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract C04.*
- Real-world clinico-pathological features of advanced biliary tract cancer (ABC) long-term survivors (LS). Salati M, Caputo F, Rimini M, Spallanzani A, Marcheselli L, **Gelsomino F**, Andrikou K, Zironi S, Di Emidio K, Clo' V, Luppi G, Braconi C and Cascinu S. Tumori Journal. Volume 104, 2018 4S. Abstract Book of the 20th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract C10.*
- A randomized phase II trial of CAPTEM or FOLFIRI as SEcondline therapy in NEuroendocrine CArcinomas and exploratory analysis of the predictive role of PET imaging and biological markers (SENECA study). Bongiovanni A, Pusceddu S, Leo S, Di Meglio G, **Gelsomino F**, Pucci F, Berardi R, Marconcini R, Lolli I, Bergamo F, Campana D, Santini D, Pastorelli D, Tamberi S, Silvestris N, Silvestris F, Buonadonna A, Russo A, Liverani C and Ibrahim T. Tumori Journal. Volume 104, 2018 4S. Abstract Book of the 20th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract P05.*
- CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study). A Bongiovanni, S Pusceddu, S Leo, G Di meglio, **F Gelsomino**, F Pucci, R Berardi, S Ricci, I Lolli, F Bergamo, D Campana, D Santini, S Tamberi, D Pastorelli, M Cives, N Silvestris, A Russo, A Buonadonna, F Foca, T Ibrahim. Annals of Oncology, Volume 29, Issue suppl_8, 1 October 2018. *Poster.*
- A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (ABTC) receiving first-line chemotherapy (1-line cht). M Salati, F Caputo, A Spallanzani, M Rimini, **F Gelsomino**, K Andrikou, S Cascinu. Annals of Oncology, Volume 29, Issue suppl_8, 1 October 2018. *Poster.*
- Second-line chemotherapy in advanced biliary tract cancer: Who may benefit? Massimiliano Salati, Francesco Caputo, Luigi Marcheselli, Margherita Rimini, Andrea Spallanzani, **Fabio Gelsomino**, Kalliopi Andrikou, Sandra Zironi, Katia Di Emidio, Vera Clo', Gabriele Luppi, Stefano Cascinu. J Clin Oncol 37, 2019 (suppl 4; abstr 381). *Poster.*
- Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz-Josef Lenz, **Fabio Gelsomino**, Massimo Aglietta, Michael Morse, Eric Van Cutsem, Raymond S. McDermott, Andrew G Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Ajlan Atasoy, Huanyu Zhao, Ming Lei, Scott Kopetz, Thierry Andre. J Clin Oncol 37, 2019 (suppl 4; abstr 635). *Abstract.*
- Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, **Gelsomino F**, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V, Loupakis F, Fassan M. Clin Cancer Res. 2019 Jul 1;25(13):3954-3961. *Original Article.*
- The treatment of rectal cancer with synchronous liver metastases: A matter of strategy. **Gelsomino F**, Spallanzani A, Garajová I. Crit Rev Oncol Hematol. 2019 Jul;139:91-95. *Review Article.*
- Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study. Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini I,

Spallanzani A, **Gelsomino F**, Corbelli J, Marisi G, Ruscelli S, Valgiusti M, Frassinetti GL, Passardi A. Cancer Manag Res. 2019 May 10;11:4357-4369. *Original Article*.

- The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. Salati M, Caputo F, Cunningham D, Marcheselli L, Spallanzani A, Rimini M, **Gelsomino F**, Reggiani-Bonetti L, Andrikou K, Rovinelli F, Smyth E, Baratelli C, Kouvelakis K, Kalaitzaki R, Gillbanks A, Michalarea V, Cascinu S, Braconi C. Eur J Cancer. 2019 Jul 2;117:84-90. *Original Article*.
- Is there an optimal choice in refractory colorectal cancer? A network meta-analysis. A Casadei Gardini, **F Gelsomino**, A Spallanzani, E Tamburini, M Scartozzi, S Cascinu. Annals of Oncology, Volume 30, Issue Supplement_4, July 2019. *Poster*.
- Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs). M Salati, S Pipitone, M Rimini, **F Gelsomino**, A Casadei Gardini, K Andrikou, F Schipilliti, G Cortesi, L Cassanelli, E Caffari, F Serra, A Ricciardolo, N De Ruvo, R Gelmini, S Cascinu, A Spallanzani. Annals of Oncology, Volume 30, Issue Supplement_4, July 2019. *Poster*.
- Non-conventional doses of somatostatin analogs in patients with progressing well differentiated neuroendocrine tumor. Lamberti G, Faggiano A, Brighi N, Tafuto S, Ibrahim T, Brizzi MP, Pusceddu S, Albertelli M, Massironi S, Panzuto F, Badalamenti G, Riccardi F, Butturini G, **Gelsomino F**, De Divitiis C, Modica R, Bongiovanni A, La Salvia A, Torchio M, Colao A, Ferone D, Campana D; ItaNet. J Clin Endocrinol Metab. 2019 Sep 23. doi: 10.1210/clinem/dgz035. [Epub ahead of print]. *Original Article*.
- BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A, Andrikou K, Cascinu S, **Gelsomino F**. Int J Mol Sci. 2019 Oct 28;20(21). *Review*.
- An italian observational, multicenter, retrospective study in patients with stage iv right-sided colon cancer. **Gelsomino F**, Garajová I, Spallanzani A, Caputo F, Lodesani M, Santini C, Andrikou K, Salati M, Bardasi C, Cerma K, Casadei Gardini A, Tamberi S, Vecchiarelli S, Tamburini E, Pagan F, Frassinetti L, Luppi G, Cascinu S. Tumori Journal. Volume 105, Number 6S, November 2019. Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract A16*.
- The prognostic nutritional index (pni) is an independent predictor of survival in advanced biliary cancers (abc) receiving first-line chemotherapy (1L). Cerma K, Caputo F, Salati M, Spallanzani A, Andrikou K, **Gelsomino F**, Rimini M, Pipitone S, Molinaro E, Orsi G, Rovesti G, Cortesi G, Schipilliti F, Bardasi C, Riggi L, Canino F, Santini C, Cascinu S, Casadei Gardini A. Tumori Journal. Volume 105, Number 6S, November 2019. Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract B03*.
- User-friendly scoring system and nomogram to predict relapse-free survival (RFS) in western patients (pts) with resected gastric cancer (GC). Rimini M, Salati M, Pipitone S, **Gelsomino F**, Casadei Gardini A, Andrikou K, Schipilliti F, Cortesi G, Cassanelli L, Caffari E, Serra F, Ricciardolo A, De Ruvo N, Gelmini R, Cascinu S, Spallanzani A. Tumori Journal. Volume 105, Number 6S, November 2019. Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract B13*.
- High doses of somatostatin analogs in well differentiated NENs: safety and efficacy in elderly. Badalamenti G, Cani M, Incorvaia L, Brighi N, Campana D, Faggiano A, **Gelsomino F**, La Salvia A, Albertelli M, Massironi S, Ibrahim T, Pusceddu S, Butturini G, Riccardi F, Tafuto S, Fanale D, Bazan V, De Luca I, Russo A. Tumori Journal. Volume 105, Number 6S, November 2019. Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM). *Abstract N06*.
- Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. Andrea Casadei-Gardini, Leonardo Solaini, Laura Riggi, Eleonora Molinaro, Vincenzo Dadduzio, Mario Domenico Rizzato, Antonio Pellino, Luca Faloppi, Giorgia Marisi, Paola Ulivi, Matteo Canale, Giulia Orsi, Giulia Rovesti, Kalliopi Andrikou, Andrea Spallanzani, **Fabio Gelsomino**, Francesco Giuseppe Foschi, Fabio Conti, Alessandro Cucchetti, Giorgio Ercolani, Paola Biason, Sara Lonardi, Stefano Cascinu, Mario Scartozzi. Gastrointest Tumors, 6 (3-4), 71-80 Oct 2019. *Original Article*.
- The Prognostic Nutritional Index Predicts Survival and Response to First-Line Chemotherapy in Advanced Biliary Cancer. Massimiliano Salati, Roberto Filippi, Caterina Vivaldi, Francesco Caputo, Francesco Leone, Francesca Salani, Krisida Cerma, Massimo Aglietta, Lorenzo Fornaro, Elisa Sperti, Massimo Di Maio, Cinzia Ortega, Elisabetta Fenocchio, Pasquale Lombardi, Celeste Cagnazzo, Iaria Depretis, **Fabio Gelsomino**, Andrea Spallanzani, Daniele Santini, Nicola Silvestris, Giuseppe Aprile, Giandomenico Roviello, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini. Liver Int, 2019 Nov 27[Online ahead of print]. *Original Article*.
- Biliary tract cancer (BTC) in the elderly: A real-world tertiary cancer center experience. Massimiliano Salati, Francesco Caputo, Krisida Cerma, Andrea Spallanzani, **Fabio Gelsomino**, Chiara Santini, Alessandro Bocconi, Maria Laura Riggi,

PROCEEDINGS

- G. Luppi, **F. Gelsomino**, A. Spallanzani. Sorafenib: risultati, limiti, indicazioni, impiego pratico. 1° Workshop AME in Endocrinologia Oncologica GEO-AME 2012.
- G. Luppi, **F. Gelsomino**. Tossicità delle terapie biologiche. 2° Workshop AME in Endocrinologia Oncologica. GEO-AME 2013.
- G. Ponti, G. Pellacani, L. Simi, R. Depenni, A. Spallanzani, **F. Gelsomino**, A. Pollio, S. Borsari, A. Fabiano, V.D. Mandel, A. Tomasi, G. Luppi. Mutazioni somatiche di BRAF in pazienti affetti da melanoma maligno metastatico ed efficacia clinica degli approcci terapeutici a bersaglio molecolare con inibitori di BRAF. XV Congresso Nazionale SIGU 2012, abstract p404.
- Artale S., Nasti G., Ronzoni M., Brugnattelli S., Zampino G., Bordonaro R., Sartore Bianchi A., Caruso M., **Gelsomino F.**, Onofri A., Rojas Llimpe F.L., Capussotti L., Vanzulli A., Angelini V. Interim analysis results of ABOVE phase II study with bevacizumab in patients with initially non resectable/borderline resectable colorectal liver-limited metastases. XV National Congress of Medical Oncology 2013, abstract A10.
- Spallanzani A., Marra L., **Gelsomino F.**, Madrigali S., Bertolini F., Depenni R., Cantile F., Fontana A., Masini C., D'Angelo E., Ghidini A., Parmiggiani M., Ponti G., Luppi G. The prognostic role of HPV status in oropharyngeal cancer: a single institution experience. XV National Congress of Medical Oncology 2013, abstract B9.
- Ponti G., Depenni R., Luppi G., Ruini C., **Gelsomino F.**, Loschi P., Tomasi A., Spallanzani A., Pellacani G. Multiple tumor phenotypes and malignant melanoma: the role of genetic testing for MITF, PTEN and CDKN2A. XV National Congress of Medical Oncology 2013, abstract C10.
- **Gelsomino F.**, Fontana A., Spallanzani A., Bertolini F., Zironi S., Depenni R., Masini C., Madrigali S., Luppi G. Irinotecan-based regimen as second-line chemotherapy in patients with metastatic neuroendocrine carcinomas: Experience in nine cases. XV National Congress of Medical Oncology 2013, abstract D6.
- Sabbatini R., Iacovelli R., Derosa L., Procopio G., Alesini D., Cortesi E., Modica D., Galli L., Clò V, **Gelsomino F.**, Cantile F., Toss A., Dominici M., Mighali P., Del Giovane C, Masini C. PSA decrease during Enzalutamide treatment in castration-resistant prostate cancer (CRPC) patients: results from name patient program (NPP) in 4 Italian institutions. XV National Congress of Medical Oncology 2013, abstract G26.
- Spallanzani Andrea, **Gelsomino Fabio**, Tamma Valentina, Depenni Roberta, Fontana Annalisa, Luppi Gabriele. The Role of bevacizumab in recurrent high grade gliomas: a single institution experience. XVI National Congress of Medical Oncology 2014, abstract R06.
- Thierry André, Sara Lonardi, Ka Yeung Mark Wong, Heinz-Josef Lenz, **Fabio Gelsomino**, Massimo Aglietta Michael Morse, Eric Van Cutsem, Ray McDermott, Andrew Graham Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A. Moss, Jean-Marie Ledezine, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Michael J. Overman. Nivolumab + Ipilimumab Combination in Patients With DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer: First Report of the Full Cohort From CheckMate-142. 2018 Gastrointestinal Cancer Symposium. Abstract 553.
- Michael J. Overman, Francesca Bergamo Ray McDermott, Massimo Aglietta, Franklin Chen, **Fabio Gelsomino**, Ka Yeung Mark Wong, Michael Morse, Eric Van Cutsem, Alain Hendlisz, Bart Neyns, Rebecca A. Moss, Huanyu Zhao, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André. Nivolumab in Patients With DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer: Long-Term Survival According to Prior Line of Treatment From CheckMate-142. 2018 Gastrointestinal Cancer Symposium. Abstract 554.
- Scott Kopetz, Thierry André, Michael J. Overman, Vittorina Zagonel, Sara Lonardi, Massimo Aglietta, **Fabio Gelsomino**, Ray McDermott, Ka Yeung Mark Wong, Alain Hendlisz, Pilar Garcia Alfonso, Heinz-Josef Lenz, Alice Walsh, Rebecca A. Moss, Danielle Greenawalt, Z. Alexander Cao. Exploratory Analysis of Janus Kinase 1 (JAK1) Loss-of-Function Mutations in Patients With DNA Mismatch Repair-deficient/Microsatellite Instability-high Metastatic Colorectal Cancer Treated With Nivolumab + Ipilimumab in CheckMate-142. American Association for Cancer Research. 109th Annual Meeting.
- Scott Kopetz, Thierry André, Michael J. Overman, Vittorina Zagonel, Sara Lonardi, Massimo Aglietta, **Fabio Gelsomino**, Ray McDermott, Ka Yeung Mark Wong, Alain Hendlisz, Pilar Garcia Alfonso, Heinz-Josef Lenz, Alice Walsh, Rebecca A. Moss, Danielle Greenawalt, Z. Alexander Cao. Exploratory Analysis of Janus Kinase 1 (JAK1) Loss-of-Function Mutations in Patients With DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer Treated With

Nivolumab + Ipilimumab in CheckMate-142. American Association for Cancer Research (AACR) Annual Meeting, April 14–18, 2018, Chicago, IL. Abstract 2603.

- Scott Kopetz, Zachary Boyd, Thierry André, Michael J. Overman, Vittorina Zagonel, Sara Lonardi, Massimo Aglietta, **Fabio Gelsomino**, Ray McDermott, Ka Yeung Mark Wong, Alain Hendlisz, Pilar Garcia Alfonso, Heinz-Josef Lenz, Alice Walsh, Rebecca A. Moss, Danielle Greenawalt, Z. Alexander Cao. Exploratory Analysis of Janus Kinase 1 Loss-of-Function Mutations in Patients With DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer Treated With Nivolumab + Ipilimumab in CheckMate 142. Association of Molecular Pathology (AMP) Europe Congress, April 30–May 2, 2018, Rotterdam, Oral Presentation.
- Bongiovanni A, Pusceddu S, Leo S, Di Meglio G, **Gelsomino F**, Pucci F, Berardi R, Ricci S, Lolli I, Bergamo F, Campana D, Santini D, Tamberi S, Pastorelli D, Silvestris N, Silvestris F, Buonadonna A, Badalamenti G, Liverani C, Ibrahim T. A Randomized Phase II Trial of CAPTEM or FOLFIRI as Second-Line Therapy in NEuroendocrine CArcinomas and Exploratory Analysis of the Predictive Role of PET Imaging and Biological Markers (SENECA Study). 16th Annual ENETS Conference, Abstract P01.

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003 e all'art. 13 del Regolamento UE 2016/679 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali.